Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

Idoroenyi Amanama Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USACorrespondence[email protected]

https://orcid.org/0000-0003-4819-4628

Dat Ngob Department of Clinical Pharmacology, City of Hope, Duarte, CA, USA

Vinod Pullarkata Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA

https://orcid.org/0000-0001-9129-3424

Ibrahim Aldossa Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA

https://orcid.org/0000-0001-9564-4498

References

Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109(3):944–950.
PubMed Web of Science ®Google Scholar
Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
PubMed Web of Science ®Google Scholar
Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016;375(8):740–753.
PubMed Web of Science ®Google Scholar
Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021;398(10299):491–502.
PubMed Web of Science ®Google Scholar
Lamb YN. Inotuzumab ozogamicin: first global approval. Drugs. 2017;77(14):1603–1610.
PubMed Web of Science ®Google Scholar
Rosner MH, Jhaveri KD, McMahon BA, et al. Onconephrology: the intersections between the kidney and cancer. CA Cancer J Clin. 2021;71(1):47–77.
PubMed Web of Science ®Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Inotuzumab ozogamicin is deliverable in relapsed ALL patients with end-stage renal disease on hemodialysis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date